OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, et al.
Cancer Discovery (2016) Vol. 7, Iss. 3, pp. 252-263
Open Access | Times Cited: 466
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, et al.
Cancer Discovery (2016) Vol. 7, Iss. 3, pp. 252-263
Open Access | Times Cited: 466
Showing 1-25 of 466 citing articles:
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo‐Jack, Alice T. Shaw
Nature Reviews Clinical Oncology (2017) Vol. 15, Iss. 2, pp. 81-94
Closed Access | Times Cited: 2920
Ibiayi Dagogo‐Jack, Alice T. Shaw
Nature Reviews Clinical Oncology (2017) Vol. 15, Iss. 2, pp. 81-94
Closed Access | Times Cited: 2920
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1722
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1722
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 5, pp. 671-684
Open Access | Times Cited: 1271
Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 5, pp. 671-684
Open Access | Times Cited: 1271
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John Primrose, Richard Fox, Daniel H. Palmer, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 5, pp. 663-673
Open Access | Times Cited: 986
John Primrose, Richard Fox, Daniel H. Palmer, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 5, pp. 663-673
Open Access | Times Cited: 986
Application of Cell-free DNA Analysis to Cancer Treatment
Ryan B. Corcoran, Bruce A. Chabner
New England Journal of Medicine (2018) Vol. 379, Iss. 18, pp. 1754-1765
Closed Access | Times Cited: 778
Ryan B. Corcoran, Bruce A. Chabner
New England Journal of Medicine (2018) Vol. 379, Iss. 18, pp. 1754-1765
Closed Access | Times Cited: 778
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 683
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 683
Biliary tract cancer
Juan W. Valle, Robin Katie Kelley, Bruno Nervi, et al.
The Lancet (2021) Vol. 397, Iss. 10272, pp. 428-444
Closed Access | Times Cited: 670
Juan W. Valle, Robin Katie Kelley, Bruno Nervi, et al.
The Lancet (2021) Vol. 397, Iss. 10272, pp. 428-444
Closed Access | Times Cited: 670
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
Lichun Ma, Maria O. Hernandez, Yongmei Zhao, et al.
Cancer Cell (2019) Vol. 36, Iss. 4, pp. 418-430.e6
Open Access | Times Cited: 617
Lichun Ma, Maria O. Hernandez, Yongmei Zhao, et al.
Cancer Cell (2019) Vol. 36, Iss. 4, pp. 418-430.e6
Open Access | Times Cited: 617
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve A. Lowery, Rachna T. Shroff, et al.
Journal of Clinical Oncology (2017) Vol. 36, Iss. 3, pp. 276-282
Open Access | Times Cited: 615
Milind Javle, Maeve A. Lowery, Rachna T. Shroff, et al.
Journal of Clinical Oncology (2017) Vol. 36, Iss. 3, pp. 276-282
Open Access | Times Cited: 615
FGF/FGFR signaling in health and disease
Yangli Xie, Nan Su, Jing Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 598
Yangli Xie, Nan Su, Jing Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 598
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar, Siyuan Zheng, Marie‐Claude Gingras, et al.
Cell Reports (2017) Vol. 18, Iss. 11, pp. 2780-2794
Open Access | Times Cited: 538
Farshad Farshidfar, Siyuan Zheng, Marie‐Claude Gingras, et al.
Cell Reports (2017) Vol. 18, Iss. 11, pp. 2780-2794
Open Access | Times Cited: 538
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle, Ángela Lamarca, Lipika Goyal, et al.
Cancer Discovery (2017) Vol. 7, Iss. 9, pp. 943-962
Open Access | Times Cited: 528
Juan W. Valle, Ángela Lamarca, Lipika Goyal, et al.
Cancer Discovery (2017) Vol. 7, Iss. 9, pp. 943-962
Open Access | Times Cited: 528
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
Ryan B. Corcoran, Thierry André, Chloé E. Atreya, et al.
Cancer Discovery (2018) Vol. 8, Iss. 4, pp. 428-443
Open Access | Times Cited: 502
Ryan B. Corcoran, Thierry André, Chloé E. Atreya, et al.
Cancer Discovery (2018) Vol. 8, Iss. 4, pp. 428-443
Open Access | Times Cited: 502
The emerging role of cell-free DNA as a molecular marker for cancer management
Abel J. Bronkhorst, Vida Ungerer, Stefan Holdenrieder
Biomolecular Detection and Quantification (2019) Vol. 17, pp. 100087-100087
Open Access | Times Cited: 486
Abel J. Bronkhorst, Vida Ungerer, Stefan Holdenrieder
Biomolecular Detection and Quantification (2019) Vol. 17, pp. 100087-100087
Open Access | Times Cited: 486
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery, Ryan Ptashkin, Emmet Jordan, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 17, pp. 4154-4161
Open Access | Times Cited: 458
Maeve A. Lowery, Ryan Ptashkin, Emmet Jordan, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 17, pp. 4154-4161
Open Access | Times Cited: 458
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R. Parikh, Ignaty Leshchiner, Liudmila Elagina, et al.
Nature Medicine (2019) Vol. 25, Iss. 9, pp. 1415-1421
Open Access | Times Cited: 432
Aparna R. Parikh, Ignaty Leshchiner, Liudmila Elagina, et al.
Nature Medicine (2019) Vol. 25, Iss. 9, pp. 1415-1421
Open Access | Times Cited: 432
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard, John J. Vincent, Stefanie Mortimer, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 15, pp. 3539-3549
Open Access | Times Cited: 382
Justin I. Odegaard, John J. Vincent, Stefanie Mortimer, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 15, pp. 3539-3549
Open Access | Times Cited: 382
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Luigi Formisano, Yao Lu, Alberto Servetto, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 331
Luigi Formisano, Yao Lu, Alberto Servetto, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 331
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 2, pp. 165-171
Open Access | Times Cited: 328
Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 2, pp. 165-171
Open Access | Times Cited: 328
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 15, pp. 3528-3538
Open Access | Times Cited: 326
Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 15, pp. 3528-3538
Open Access | Times Cited: 326
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre, Jonathan A. Nowak, Nicholas D. Camarda, et al.
Cancer Discovery (2018) Vol. 8, Iss. 9, pp. 1096-1111
Open Access | Times Cited: 323
Andrew J. Aguirre, Jonathan A. Nowak, Nicholas D. Camarda, et al.
Cancer Discovery (2018) Vol. 8, Iss. 9, pp. 1096-1111
Open Access | Times Cited: 323
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal, Lei Shi, Leah Y. Liu, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1064-1079
Open Access | Times Cited: 321
Lipika Goyal, Lei Shi, Leah Y. Liu, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1064-1079
Open Access | Times Cited: 321
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley, John Bridgewater, Gregory J. Gores, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 353-363
Open Access | Times Cited: 321
Robin Kate Kelley, John Bridgewater, Gregory J. Gores, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 353-363
Open Access | Times Cited: 321
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 318
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 318
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
The Lancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 10, pp. 803-815
Closed Access | Times Cited: 317
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
The Lancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 10, pp. 803-815
Closed Access | Times Cited: 317
